Literature DB >> 19459859

Manual vacuum aspiration: a safe alternative for the surgical management of early pregnancy loss.

D S Milingos1, M Mathur, N C Smith, P W Ashok.   

Abstract

Manual vacuum aspiration (MVA) is an alternative to the standard surgical curettage, performed under local anaesthetic in the setting of a treatment room. The aim of our study was to assess the efficacy of MVA in the management of first trimester early fetal demise and first- and mid-trimester incomplete miscarriage. This was a retrospective study of 246 patients who were scheduled to undergo MVA for first trimester early fetal demise and first- and mid-trimester incomplete miscarriage. One woman was excluded in the analysis because of the procedure being abandoned prior to MVA. Efficacy of the procedure was 94.7% (232/245). Incomplete uterine evacuation was seen in 5.3% (13/245) patients. Although not widely used in the UK, MVA could be considered routinely, thus avoiding general anaesthesia and the need for access to theatre.

Entities:  

Mesh:

Year:  2009        PMID: 19459859     DOI: 10.1111/j.1471-0528.2009.02223.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  3 in total

Review 1.  Surgical procedures for evacuating incomplete miscarriage.

Authors:  Ozge Tunçalp; A Metin Gülmezoglu; João Paulo Souza
Journal:  Cochrane Database Syst Rev       Date:  2010-09-08

2.  A survey of manual vacuum aspiration's experiences among the new medical graduates in Thailand.

Authors:  Rapeepong Suphanchaimat; Nongluk Boonthai; Sasikan Tangthasana; Weerasak Putthasri; Viroj Tangcharoensathien; Kamheang Chaturachinda
Journal:  Reprod Health       Date:  2013-09-11       Impact factor: 3.223

3.  Economic evaluation of a randomized controlled trial comparing mifepristone and misoprostol with misoprostol alone in the treatment of early pregnancy loss.

Authors:  Charlotte C Hamel; Marcus P L M Snijders; Sjors F P J Coppus; Frank P H A Vandenbussche; Didi D M Braat; Eddy M M Adang
Journal:  PLoS One       Date:  2022-02-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.